Beranda › Limfoma Burkitt › Minnesota
Uji klinis Limfoma Burkitt di Minnesota
10 studi untuk Limfoma Burkitt mencari peserta di lokasi di Minnesota.
Kota di Minnesota
Teks studi resmi (Bahasa Inggris)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
Menerima pesertaFase 2
366 Days – 46 Years · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Essentia Health Cancer Center, Duluth
- Abbott-Northwestern Hospital, Minneapolis
- Mayo Clinic in Rochester, Rochester
Menerima pesertaFase 3
Usia 18 hingga 39 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Minnesota/Masonic Cancer Center, Minneapolis
Menerima pesertaFase 2
365 Days · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06317662Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Minnesota, Minneapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
Menerima pesertaFase 2
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
Menerima pesertaFase 3
365 Days – 25 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospitals and Clinics of Minnesota, Minneapolis
Menerima pesertaFase 2
Usia 7 hingga 25 · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
Menerima pesertaFase 2
Hingga usia 75 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
Menerima pesertaFase 2
Hingga usia 60 · Semua jenis kelamin · Diperbarui 25 Jun 2026 · NCT03314974Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.